OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Nikolaus Schultz, Jianjiong Gao et al.|JCO Precision Oncology|2017Cited by 2.7k
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J. Harding, Sebastián Mondaca, Feng Xie et al.|The Lancet Oncology|2023Cited by 243
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 AntibodyJames J. Harding|Clinical Cancer Research|2021Cited by 157
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract CancerDarren Cowzer, James J. Harding, Madison Darmofal et al.|JCO Precision Oncology|2025Cited by 3
Supplementary data1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, James J. Harding|Unknown|2025Cited by 0